A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Recruiting now · Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients. The primary objective is to assess Progression-Free Survival (PFS) per RECIST v1.1. Secondary objectives include Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), and safety. Approximately 36 participants will receive induction therapy (Chidamide + chemotherapy + PD-L1 inhibitor) for 4 cycles, followed by Chidamide maintenance until progression or unacceptable toxicity.

Key facts

Study ID

NCT07373964

Run by

China Medical University, China

People needed

36

Starts

2025-10-15

Expected to finish

2027-10-14

Last updated by the study team

2026-01-28

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 and ≤75 years.
• Histologically confirmed ES-SCLC, unsuitable for local radical therapy.
• No prior systemic therapy for ES-SCLC.
• ECOG performance status 0-1.
• At least one measurable lesion per RECIST v1.1.
• Expected survival ≥3 months.
• Adequate organ function (hematological, hepatic, renal, cardiac).
• Effective contraception from consent until 180 days after last dose.
• For active HBV infection: HBV DNA <2000 IU/mL within 28 days before treatment and on stable antiviral therapy.
• Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).
• Signed informed consent.

You may not qualify if…

• Factors significantly affecting oral drug absorption.
• Prior HDAC inhibitor or immune checkpoint inhibitor therapy.
• Known allergy to any study drug component.
• Other malignancy within past 5 years (except certain cured cancers).
• Participation in another clinical trial within 4 weeks.
• Immunodeficiency, HIV positivity, or organ transplant history.
• Uncontrolled cardiovascular disease or QTc >450 ms.
• Pregnancy, lactation, or unwillingness to use effective contraception.
• Other severe comorbid conditions deemed unsafe by investigator.
• History of neurological or psychiatric disorders.
• Any condition making the patient unsuitable per investigator judgment.

Where it is running

• The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.